Healthy Skepticism Library item: 10439

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Faunce TA.
Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia’s Pharmaceutical Benefits Scheme?
Med J Aust 2007 Jun 13; 187:(4):240-242
http://www.mja.com.au/public/issues/187_04_200807/fau10585_fm.html

Abstract:

Unless the federal government changes the course of our medicines policy with intention, Australia’s pricing of patented pharmaceuticals is likely to follow inequitable US trends

Introduction – What is reference pricing? – What are the amendments influencing reference pricing? – What lies behind these changes? – The PBS beyond Australia – The end of public-funded medicines? – Competing interests – Author details – References

Proposed amendments to the National Health Act 1953 (Cwlth) are currently being considered by the Australian federal government. The National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007 (the Bill) includes several changes that will limit reference pricing under the Australian Pharmaceutical Benefits Scheme (PBS). Here, I argue that these amendments have been influenced by the Australia–United States Free Trade Agreement (AUSFTA) and, further, that if US influence on Australian medicines policy continues, there are likely to be adverse consequences for all Australians, involving the erosion of scientific objectivity and equity in PBS processes and, eventually, the end of public-funded medicines…

Notes:

Free full text